Press Release, Helsinki, 27 October 2020 at 12.00 pm (EET)
Nexstim Has Received Three NBS System Orders in Europe
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that it has received three NBS System orders in Europe in October.
One order is from a hospital that now starts to use the Nexstim NBS System with SmartFocus nTMS technology for the first time. Two of the orders are for NBS System Upgrades, where a new Nexstim NBS System with the latest SmartFocus nTMS features will replace the hospital's older NBS system.
Nexstim NBS systems with SmartFocus nTMS are mainly used for neurosurgical diagnostics: One of the most crucial pieces of information needed for neurosurgery or radiotherapy is the tumour's or other lesion's location in relation to the essential functions and their connections in the patient's brain. SmartFocus nTMS mapping with Nexstim's NBS system can give this information regarding motor and speech areas - it can be invaluable when deciding the best treatment option.
Mikko Karvinen, CEO of Nexstim, commented: "We are happy to announce these orders both from our existing and new customers as one of our key strategic objectives in the NBS business is to develop new sales and grow the recurring revenue through our existing installed base. Our NBS System with SmartFocus nTMS is a unique tool: According to studies, the integration of SmartFocus nTMS into the surgical workflow crucially improves pre-operative planning, patient counselling, and surgical procedure.1"
1)Frey D. et al. Navigated transcranial magnetic stimulation improves the treatment outcome in patients with brain tumors in motor eloquent locations Neuro-Oncology. 2014 Jun 12.
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com
About Nexstim Plc
Nexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
SmartFocus technology is used in Nexstim's proprietary Navigated Brain Therapy (NBT) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT system is CE marked for the treatment of major depression and chronic neuropathic pain.
In addition, Nexstim is commercializing its SmartFocus based Navigated Brain Stimulation (NBS) system for diagnostic applications. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.
For more information please visit www.nexstim.com
Attachment
- Nexstim Plc_Press Release_NBS 5 Orders_EN_Final (https://ml-eu.globenewswire.com/Resource/Download/9867a5a2-eed5-40f9-a3ca-a9e254cc8a50)
